President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics ...

Vinay Prasad oversees vaccines, gene therapies and the blood supply. His views raise alarms for pharmaceutical companies and ...

While Prasad’s views may not align with many of the FDA’s traditional policies, they do fit into a broader MAHA agenda of ...

The United States Food and Drug Administration has chosen Dr Vinay Prasad to lead its Center for Biologics Evaluation and Research.

Axon named Tina Hahn as president and managing partner. Bristol Myers Squibb promoted Cari Gallman to EVP, general counsel ...

A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.

One day after he was named the director of the FDA’s Center for Biologics Evaluation and Research, Vinay Prasad showed up at ...

Matthew Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health ...

Republicans on Capitol Hill are struggling to reach consensus on cutting the Medicaid program as they search for nearly a ...

What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

During his first term, attempts by President Donald Trump to slash drug price | After failing in his first term to install a most favored nation plan to reduce drug prices, President Donald Trump is ...